Protocol update and baseline characteristics for the TRIal to slow the Progression of Diabetes (TRIPOD) randomized controlled trial

Joann Bairavi, Daphne Gardner, Ester Yeoh, Kwang Wei Tham, Mihir Gandhi, Ngiap Chuan Tan, Phong Ching Lee, Robyn Su May Lim, Thofique Adamjee, Yin Bun Cheung, Yong Mong Bee, Eric FinkelsteinTrials 2023 · DOI

TL;DR

This paper updates the protocol for the TRIPOD trial, a randomized controlled study investigating a diabetes management package (DMP) with or without financial incentives to slow the progression of Type 2 Diabetes (T2D). Due to recruitment challenges, the study refined its design, sample size, and primary hypothesis to focus on the combined DMP and incentive arm versus usual care, providing valuable insights into adapting clinical trials during unforeseen circumstances.

What Problem Does This Paper Address?

Type 2 Diabetes (T2D) is a growing global health concern, significantly increasing the risk of cardiovascular disease and other adverse health outcomes. Singapore, like many nations, faces a rising T2D prevalence. The TRIPOD trial was initially designed to assess whether a comprehensive diabetes management package (DMP) – including a mobile app, health coaching, and monitoring devices – could improve glycemic control (measured by HbA1c levels) in individuals with T2D. The study also aimed to evaluate the added benefit of a financial rewards scheme (M-POWER rewards) integrated into the DMP. However, the trial encountered significant recruitment challenges, exacerbated by the COVID-19 pandemic, necessitating a protocol update to ensure the study's objectives could still be met within the allocated budget and timeframe. This paper addresses the need to adapt and refine clinical trial protocols in response to real-world operational hurdles while maintaining scientific rigor.

Methods

The TRIPOD trial is a randomized controlled trial. The original protocol involved a 1:1:1 allocation ratio across three arms: Usual Care, DMP, and DMP + M-POWER rewards. However, to overcome recruitment difficulties, several key changes were implemented and are detailed in this manuscript:

  • Arm Allocation Ratio: Modified from 1:1:1 to a 10:1:10 ratio (Usual Care: DMP: DMP + M-POWER rewards). This change allowed for a reduction in the overall sample size.
  • Sample Size: Reduced from 339 to 269 participants.
  • Intervention Period: Shortened from two years to one year.
  • Primary Hypothesis: Refocused solely on the comparison between the Usual Care arm and the DMP + M-POWER rewards arm, simplifying the primary analysis. The DMP-only arm is now primarily for process evaluation.
  • Assessments: Month 18 and 24 assessments were dropped, with all primary and secondary hypotheses now tested at months 6 and 12.
  • Sampling Frame: Expanded from 11 referral sites to a country-wide approach.
  • Eligibility Criteria: Adjusted to increase enrollment, including extending the window period for HbA1c tests and removing a conditional eligibility criterion.
  • Data Collection Tools: Modifications were made to address technical issues with specific devices and apps, including the replacement of RxCap pill trackers with advice to use the Medisafe app for medication adherence and the manual entry of some glucometer data.
  • Payouts: Revised to potentially reduce attrition, with increases for attending training and assessments, and adjustments to fairness payouts.

The study adheres to the Consolidated Standards of Reporting Trials (CONSORT) statement.

Datasets

The study utilizes data collected from participants enrolled in the TRIPOD trial. No new datasets or benchmarks were introduced in this paper; rather, it reports on the baseline characteristics of the participants recruited for the modified trial.

Key Insights and Ideas

  • Adaptability of Clinical Trials: The paper highlights the critical need for flexibility and adaptation in clinical trial design when faced with unforeseen challenges like recruitment difficulties and global health crises (e.g., COVID-19). The TRIPOD team successfully modified their protocol to salvage the study's core objectives.
  • Impact of Incentives: By shifting the primary focus to the DMP + M-POWER rewards arm, the study implicitly prioritizes understanding the combined effect of a comprehensive digital health intervention and financial incentives, suggesting a strong hypothesis about their synergistic potential in diabetes management.
  • Process Evaluation Importance: The decision to use the DMP-only arm primarily for process evaluation underscores the value of understanding how interventions work, not just if they work, especially in complex mHealth interventions.
  • Challenges in mHealth Implementation: The paper candidly discusses technical issues encountered with specific apps and devices (e.g., RxCap, Contour Plus One glucometer syncing), emphasizing the ongoing challenges in seamlessly integrating technology into clinical research and practice.

Key Results

This paper focuses on the protocol update and baseline characteristics, rather than final efficacy results. However, it provides key demographic and clinical data for the recruited participants:

  • Participant Demographics:
    • Average age: 55.0 years (SD 9.7)
    • Male: 64.2%
    • Ethnicity: Majority Chinese (76.8%), followed by Indian/other (18.3%) and Malay (4.9%).
  • Household Income: 67.0% had a monthly income of SGD$4000 or more.
  • Clinical Characteristics:
    • Mean baseline HbA1c: 8.10% (SD 0.95)
    • Mean Body Mass Index (BMI): 26.8 kg/m² (SD 5.3)
  • Recruitment: 1,417 individuals were assessed for eligibility, with 269 ultimately randomized. Recruitment concluded on June 4, 2022.
  • Follow-up: Month 12 follow-up data collection concluded on June 8, 2023.

Limitations and Future Work

  • Limitations:
    • The protocol modifications, particularly the reduced sample size and narrowed primary hypothesis, may limit the power to detect smaller differences or explore secondary outcomes as originally intended.
  • Technical issues with mHealth components (apps, trackers) may have impacted data quality or participant experience in certain arms.
  • The study design now focuses on the combined DMP + M-POWER rewards arm, meaning the independent effect of the DMP alone cannot be definitively determined from the primary analysis.
  • Future Work:
    • The authors state that all pre-planned analyses will be conducted and final results reported, which will provide the efficacy outcomes of the modified trial.
  • Process evaluations of the DMP and DMP+M-POWER rewards arms are expected to offer insights into the drivers of results and the potential for sustainability of these interventions.
  • The authors suggest that if differences are identified at 12 months, future studies may be required to test for sustained effects, and if differences are not identified, it's unlikely they would materialize over a longer duration.
  • If the primary hypothesis (DMP + M-POWER vs. Usual Care) is confirmed, future studies might be needed to isolate the independent effect of the rewards program.

Summary updated

Abstract

ClinicalTrials.gov NCT03800680 . Registered on 11 January 2019.
BibTeX
@inproceedings{bairavi2023protocol,
  author = {Joann Bairavi and Daphne Gardner and Ester Yeoh and Kwang Wei Tham and Mihir Gandhi and Ngiap Chuan Tan and Phong Ching Lee and Robyn Su May Lim and Thofique Adamjee and Yin Bun Cheung and Yong Mong Bee and Eric Finkelstein},
  title = {{Protocol update and baseline characteristics for the TRIal to slow the Progression of Diabetes (TRIPOD) randomized controlled trial}},
  booktitle = {Trials},
  year = {2023},
  doi = {10.1186/s13063-023-07770-7},
}
Figure